Finally, An Apoptosis-Targeting Therapeutic for Cancer.
Resistance to cell death represents one of the hallmarks of cancer. Various genetic and epigenetic changes in malignant cells afford cytoprotection in the face of genomic instability, oncogene activation, microenvironment stress, chemotherapy, targeted anticancer drugs, and even immunotherapy. Central among the regulators of cell life and death are Bcl-2 family proteins, with the founding member of the family (B-cell lymphoma/leukemia-2) discovered via its involvement in chromosomal translocations in lymphomas. The quest for therapeutics that target cell survival protein Bcl-2 represents a long road traveled, with many dead-ends, disappointments, and delays. Finally, a Bcl-2-targeting medicine has gained approval as a new class of anticancer agent. Cancer Res; 76(20); 5914-20. ©2016 AACR.
Department of Cancer Biology and Genetics The Ohio State University and Comprehensive Cancer Center, Columbus, Ohio. Carlo.Croce@osumc.edu.
Carlo M
CM
Croce
Roche Pharmaceutical Research and Early Development, Basel, Switzerland. Department of Biology, ETH Zürich, Zürich, Switzerland.
John C
JC
Reed
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015195:Drug Design; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000502:physiology; D051020:bcl-X Protein / Q000037:antagonists & inhibitors / Q000502:physiology
D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein
Nat Cell Biol. 2002 Nov;4(11):842-9
12402042
Blood. 2005 Nov 1;106(9):3150-9
16014563
Cell. 1996 Jul 12;86(1):147-57
8689682
Blood. 1993 Sep 15;82(6):1820-8
8104532
Oncogene. 1987;2(1):3-7
3325884
J Clin Oncol. 2011 Mar 1;29(7):909-16
21282543
Curr Biol. 1997 Dec 1;7(12):913-20
9382837
Cancer Cell. 2006 Nov;10(5):375-88
17097560
Nature. 1996 May 23;381(6580):335-41
8692274
J Clin Oncol. 2012 Feb 10;30(5):488-96
22184378
J Biol Chem. 1996 Mar 29;271(13):7440-4
8631771
Cell. 1995 Jan 27;80(2):293-9
7834749
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
16166262
Blood. 2002 Feb 1;99(3):1038-43
11807010
Nature. 2005 Jun 2;435(7042):677-81
15902208
Science. 1997 Feb 21;275(5303):1132-6
9027315
N Engl J Med. 2016 Jan 28;374(4):311-22
26639348
Cell. 2011 Mar 4;144(5):646-74
21376230
EMBO J. 1997 Mar 3;16(5):968-77
9118958
Nat Med. 2013 Feb;19(2):202-8
23291630
Clin Cancer Res. 2012 Jun 1;18(11):3163-9
22496272
Lancet Oncol. 2010 Dec;11(12):1149-59
21094089
Science. 1997 Feb 14;275(5302):983-6
9020082
Mol Cell Biol. 1990 May;10(5):1901-7
2183011
Cell. 1994 Oct 21;79(2):353-64
7954801
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7
18040043
Science. 1985 Jun 21;228(4706):1440-3
3874430
Blood. 1993 Jun 1;81(11):3091-6
7684624
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2771-4
2704746
Nature. 1988 Sep 29;335(6189):440-2
3262202
J Med Chem. 1999 Jul 1;42(13):2315-7
10395471
Cancer Res. 2008 May 1;68(9):3421-8
18451170
Science. 1996 Nov 29;274(5292):1531-4
8929414
Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):18-9
25768998
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1931-6
12574499
Nature. 1988 Nov 17;336(6196):259-61
2848196
Genes Dev. 1996 Nov 15;10(22):2859-69
8918887
Cancer Res. 1990 Oct 15;50(20):6565-70
2208117
Blood. 1997 Jul 1;90(1):244-51
9207459
Haematologica. 2016 May;101(5):e185-8
26869629
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3012-7
11248023
Cancer Res. 1992 Oct 1;52(19):5407-11
1394146
Blood. 2009 Apr 30;113(18):4403-13
19008458
Cell. 1993 Aug 27;74(4):609-19
8358790
Cell. 2007 Mar 23;128(6):1173-86
17382885
J Clin Oncol. 2007 Mar 20;25(9):1114-20
17296974
Leuk Lymphoma. 2015;56(10):2826-33
25797560
Science. 1984 Nov 30;226(4678):1097-9
6093263
Antisense Res Dev. 1994 Summer;4(2):71-9
7950302
Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8
3523487
Nature. 1990 Nov 22;348(6299):334-6
2250705